Name: | Description: | Size: | Format: | |
---|---|---|---|---|
1.16 MB | Adobe PDF |
Advisor(s)
Abstract(s)
The virtual screening of a library of xanthone derivatives led us to the identification of potential novel
MDM2 ligands. The activity of these compounds as inhibitors of p53–MDM2 interaction was
investigated using a yeast phenotypic assay, herein developed for the initial screening. Using this
approach, in association with a yeast p53 transactivation assay, the pyranoxanthone (3,4-dihydro-12-
hydroxy-2,2-dimethyl-2H,6H-pyrano[3,2-b]xanthen-6-one) (1) was identified as a putative small molecule inhibitor of p53–MDM2 interaction.
The activity of the pyranoxanthone 1 as inhibitor of p53–MDM2 interaction was further investigated
in human tumor cells with wild-type p53 and overexpressed MDM2. Notably, the pyranoxanthone 1
mimicked the activity of known p53 activators, leading to p53 stabilization and activation of p53-
dependent transcriptional activity. Additionally, it led to increased protein levels of p21 and Bax, and to
caspase-7 cleavage. By computational docking studies, it was predicted that, like nutlin-3a, a known
small-molecule inhibitor of p53–MDM2 interaction, pyranoxanthone 1 binds to the p53-binding site of
MDM2.
Overall, in this work, a novel small-molecule inhibitor of p53–MDM2 interaction with a xanthone
scaffold was identified for the first time. Besides its potential use as molecular probe and possible lead to
develop anticancer agents, the pyranoxanthone 1 will pave the way for the structure-based design of a
new class of p53–MDM2 inhibitors.
Description
Keywords
Xanthone derivatives Inhibitor of p53–MDM2 interaction Computational docking Yeast-based assays Antitumor activity . Faculdade de Ciências Exatas e da Engenharia
Citation
Leão, M., Pereira, C., Bisio, A., Ciribilli, Y., Paiva, A. M., Machado, N., ... & Saraiva, L. (2013). Discovery of a new small-molecule inhibitor of p53–MDM2 interaction using a yeast-based approach. Biochemical Pharmacology, 85(9), 1234-1245.
Publisher
Elsevier